全文获取类型
收费全文 | 2250257篇 |
免费 | 184898篇 |
国内免费 | 4144篇 |
专业分类
耳鼻咽喉 | 31798篇 |
儿科学 | 71766篇 |
妇产科学 | 65139篇 |
基础医学 | 321538篇 |
口腔科学 | 66721篇 |
临床医学 | 199824篇 |
内科学 | 434237篇 |
皮肤病学 | 47354篇 |
神经病学 | 183381篇 |
特种医学 | 90493篇 |
外国民族医学 | 634篇 |
外科学 | 344045篇 |
综合类 | 59046篇 |
现状与发展 | 5篇 |
一般理论 | 803篇 |
预防医学 | 177190篇 |
眼科学 | 52661篇 |
药学 | 169682篇 |
3篇 | |
中国医学 | 4285篇 |
肿瘤学 | 118694篇 |
出版年
2018年 | 20897篇 |
2015年 | 21333篇 |
2014年 | 29769篇 |
2013年 | 45440篇 |
2012年 | 61410篇 |
2011年 | 64613篇 |
2010年 | 38053篇 |
2009年 | 36112篇 |
2008年 | 61467篇 |
2007年 | 65652篇 |
2006年 | 66150篇 |
2005年 | 64526篇 |
2004年 | 63517篇 |
2003年 | 60867篇 |
2002年 | 59240篇 |
2001年 | 100176篇 |
2000年 | 103163篇 |
1999年 | 87642篇 |
1998年 | 24970篇 |
1997年 | 22820篇 |
1996年 | 22658篇 |
1995年 | 21836篇 |
1994年 | 20653篇 |
1993年 | 19447篇 |
1992年 | 73012篇 |
1991年 | 70894篇 |
1990年 | 69448篇 |
1989年 | 67059篇 |
1988年 | 62763篇 |
1987年 | 61763篇 |
1986年 | 58704篇 |
1985年 | 56880篇 |
1984年 | 43156篇 |
1983年 | 37091篇 |
1982年 | 22649篇 |
1981年 | 20455篇 |
1980年 | 19121篇 |
1979年 | 42201篇 |
1978年 | 29794篇 |
1977年 | 25096篇 |
1976年 | 23426篇 |
1975年 | 24970篇 |
1974年 | 30771篇 |
1973年 | 29508篇 |
1972年 | 27414篇 |
1971年 | 25820篇 |
1970年 | 23977篇 |
1969年 | 22848篇 |
1968年 | 20737篇 |
1967年 | 18923篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
82.
83.
84.
Ahmed M. Abu El-Asrar Ajmal Ahmad Eef Allegaert Mohammad Mairaj Siddiquei Priscilla W. Gikandi Gert De Hertogh 《Ocular immunology and inflammation》2020,28(4):575-588
ABSTRACT
Purpose
To investigate the expression of IL-11 and its receptor IL-11Rα and to quantify density of CD163+ M2 macrophages in proliferative diabetic retinopathy (PDR). 相似文献85.
86.
87.
Purpose
Chest wall pain is an uncommon but bothersome late complication following lung stereotactic body radiation therapy. Despite numerous studies investigating predictors of chest wall pain, no clear consensus has been established for a chest wall constraint. The aim of our study was to investigate factors related to chest wall pain in a homogeneous group of patients treated at our institution.Patients and methods
All 122 patients were treated with the same stereotactic body radiation therapy regimen of 48 Gy in three fractions, seen for at least 6 months of follow-up, and planned with heterogeneity correction. Chest wall pain was scored according to the Common Terminology Criteria for Adverse Events classification v3.0. Patient (age, sex, diabetes, osteoporosis), tumour (planning target volume, volume of the overlapping region between planning target volume and chest wall) and chest wall dosimetric parameters (volumes receiving at least 30, 40, and 50 Gy, the minimal doses received by the highest irradiated 1, 2, and 5 cm3, and maximum dose) were collected. The correlation between chest wall pain (grade 2 or higher) and the different parameters was evaluated using univariate and multivariate logistic regression.Results
Median follow-up was 18 months (range: 6–56 months). Twelve patients out of 122 developed chest wall pain of any grade (seven with grade 1, three with grade 2 and two with grade 3 pain). In univariate analysis, only the volume receiving 30 Gy or more (P = 0.034) and the volume of the overlapping region between the planning target volume and chest wall (P = 0.038) significantly predicted chest wall pain, but these variables were later proved non-significant in multivariate regression.Conclusion
Our analysis could not find any correlation between the studied parameters and chest wall pain. Considering our present study and the wide range of differing results from the literature, a reasonable conclusion is that a constraint for chest wall pain is yet to be defined. 相似文献88.
R. Di Raimondo J. Sanz-Esporrn R. Pl I. Sanz-Martn F. Luengo F. Vignoletti J. Nuez Mariano Sanz 《Clinical oral investigations》2020,24(7):2351-2361
To evaluate the changes in alveolar contour after guided bone regeneration (GBR) with two different combinations of biomaterials in dehiscence defects arou 相似文献
89.
L.‐Q. Zheng X.‐C. Han Y. Huang H.‐W. Li X.‐D. Niu J. Li 《Clinical and experimental dermatology》2015,40(3):293-297
Porocarcinoma is an unusual, locally aggressive and potentially fatal neoplasm. Several cutaneous malignancies have been described in association with porocarcinoma, including squamous cell carcinoma, basal cell carcinoma and tricholemmal carcinoma. Previous reports have indicated that the occurrence of malignant tumours in combination with porocarcinoma is extremely rare, in particular with regard to Bowen disease (BD). We report an uncommon case of porocarcinoma occurring synchronously in a single BD lesion in a 63‐year‐old woman with multiple BD lesions. The clinical and histological findings confirmed this diagnosis. 相似文献
90.
Rishad R. Jivani Gaurang J. Lakhtaria Dhaval D. Patadiya Laxman D. Patel Nurrudin P. Jivani Bhagyesh P. Jhala 《Saudi Pharmaceutical Journal》2016,24(1):1-20
Advancement in microelectromechanical system has facilitated the microfabrication of polymeric substrates and the development of the novel class of controlled drug delivery devices. These vehicles have specifically tailored three dimensional physical and chemical features which together, provide the capacity to target cell, stimulate unidirectional controlled release of therapeutics and augment permeation across the barriers. Apart from drug delivery devices microfabrication technology’s offer exciting prospects to generate biomimetic gastrointestinal tract models. BioMEMS are capable of analysing biochemical liquid sample like solution of metabolites, macromolecules, proteins, nucleic acid, cells and viruses. This review summarized multidisciplinary application of biomedical microelectromechanical systems in drug delivery and its potential in analytical procedures. 相似文献